Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 54 entries
View as:

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00365183 Org: User:
Start: 06/30/06 End: 06/30/08 Due: 06/30/09

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Phase: N/A Priority: Normal
NCT ID: NCT02436668 Org: User:
Start: 05/31/15 End: 04/25/19 Due: 04/25/20

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00849654 Org: User:
Start: 02/28/09 End: 07/31/12 Due: 07/31/13

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02142049 Org: User:
Start: 05/31/14 End: 08/31/17 Due: 08/31/18

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00003563 Org: User:
Start: 08/31/98 End: 06/30/05 Due: 06/30/06

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01578707 Org: User:
Start: 06/30/12 End: 10/25/18 Due: 10/25/19

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02351037 Org: User:
Start: 02/28/15 End: 04/30/17 Due: 04/30/18

Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00121420 Org: User:
Start: - End: - Due: -

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT02401048 Org: User:
Start: 05/31/15 End: 11/30/17 Due: 11/30/18

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00134186 Org: User:
Start: - End: - Due: -

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00102505 Org: User:
Start: 11/30/04 End: - Due: -

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01962792 Org: User:
Start: 12/31/13 End: 03/31/19 Due: 03/31/20

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02077166 Org: User:
Start: 03/13/14 End: 12/17/20 Due: 12/17/21

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

Phase: N/A Priority: Normal
NCT ID: NCT03112174 Org: User:
Start: 06/29/17 End: 06/26/24 Due: 06/26/25

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Phase: N/A Priority: Normal
NCT ID: NCT01722487 Org: User:
Start: 03/31/13 End: 05/31/15 Due: 05/31/16

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01105247 Org: User:
Start: 05/31/10 End: 02/28/13 Due: 02/28/14

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00724984 Org: User:
Start: 07/31/08 End: - Due: -

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01109069 Org: User:
Start: 06/30/10 End: 04/26/19 Due: 04/26/20

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02582879 Org: User:
Start: 09/30/15 End: 07/21/21 Due: 07/21/22

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT02165397 Org: User:
Start: 07/07/14 End: 11/07/19 Due: 11/07/20

Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00080041 Org: User:
Start: - End: - Due: -

Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Phase: N/A Priority: Normal
NCT ID: NCT01236391 Org: User:
Start: 02/28/11 End: 01/31/14 Due: 01/31/15

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01478581 Org: User:
Start: 03/31/12 End: 08/31/18 Due: 08/31/19

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02599324 Org: User:
Start: 12/01/15 End: 08/20/21 Due: 08/20/22

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

Phase: N/A Priority: Normal
NCT ID: NCT01217749 Org: User:
Start: 12/31/10 End: 05/31/14 Due: 05/31/15